IRB #

STUDY00019211

Title

A Feasibility Study to Assess a Window of Opportunity Strategy for Targeted PARP or MEK Inhibition in Patients with Pancreatic Ductal Adenocarcinoma

Principal Investigator

Charles Lopez

Study Purpose

The purpose of this study is to understand the biology of your pancreatic cancer.

Medical Condition(s)

Pancreatic Ductal Adenocarcinoma, Olaparib, Cobimetinib

Eligibility Criteria

- Age ≥ 18 years or < 78 years
- Biopsy proven adenocarcinoma of the pancreas
- No history of previous chemotherapy
- No recent major surgery within 4 weeks prior to starting study treatment. Minor surgery within 2 weeks of starting study treatment. Must be recovered from effects of surgery.

Age Range

18 - 78

Healthy Volunteers Needed

No

Duration of Participation

Approximately 70 days

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

OHSU

Recruitment End

10/01/2024

Compensation Provided

No


Go Back